Ventilator-associated pneumonia (VAP) is the main cause of nosocomial infection in patients undergoing major heart surgery. An international study of 25 hospitals from 8 European countries, published in BioMed Central's open access journal Critical Care, has confirmed the degree of danger posed by VAP and identified the main risk factors.
Javier Hortal, from the Hospital General Universitario Gregorio Marañón, worked with the European Study Group on Nosocomial Infections (ESGNI) and the European Workgroup of Cardiothoracic Intensivists (EWCI) to carry out a prospective study of 971 patients undergoing major heart surgery. They found that 4.4% acquired some form of nosocomial infection and VAP accounted for almost half of these (2.1%). According to Hortal, "The crude mortality rate of patients with VAP in our study was found to be 35%, this is significantly more than the mortality rate of 2.3% seen in patients who avoided VAP. The overall mortality rate for VAP in patients undergoing MHS may be as high as 16-57%, but many critically ill patients with VAP die because of their underlying disease rather than of pneumonia, which makes analysis difficult."
The authors found that, apart from the amount of time spent on mechanical ventilation, other risk factors for the development of VAP included transfusion requirements, type of surgery and the need for re-intervention for haemorrhage or cardiac tamponade in the immediate postoperative period. Hortal said, "Most unfortunately, the majority of the variables that significantly predict VAP are not amenable to intervention."
The authors recommend that anticipative or pre-emptive antimicrobial therapy should be explored as one of the few potential interventions to avoid VAP in patients remaining under mechanical ventilation for more than 48 hours.
Notes to Editors
1. Ventilator-associated pneumonia in patients undergoing major heart surgery: an incidence study in Europe
Javier Hortal, Patricia Muñoz, Gregorio P Cuerpo, Héctor Litvan, Peter M Rosseel, Emilio Bouza, the European Study Group on Nosocomial Infections and the European Workgroup of Cardiothoracic Intensivists Critical Care (in press)
During the embargo, article available here: http://ccforum.com/imedia/1186902304221094_article.pdf?random=341597
After the embargo, article available at journal website: http://ccforum.com/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
2. Critical Care is a high quality, peer-reviewed, international clinical medical journal. Critical Care aims to improve the care of critically ill patients by acquiring, discussing, distributing, and promoting evidence-based information relevant to intensivists. The journal is edited by Prof Jean-Louis Vincent (Belgium) and has an Impact Factor of 3.83
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.